Neal Shore, MD, FACS

An expert discusses how KEYNOTE-905 sets the stage for the next generation of bladder cancer research and multidisciplinary care, shaping the evolving future of MIBC treatment.

An expert discusses strategies for optimizing perioperative immunotherapy use, managing toxicity, and ensuring adherence as KEYNOTE-905 transitions from trial evidence to clinical practice.

An expert discusses how KEYNOTE-905 establishes a new evidence-based systemic therapy option that transforms the management and prognosis of patients with muscle-invasive bladder cancer.

An expert discusses how proactive referral, multidisciplinary coordination, and early identification can optimize outcomes for patients with muscle-invasive bladder cancer, especially those with high-risk T2N0 disease.

An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, significantly improving survival outcomes and redefining curative treatment strategies.

Chandler Park, MD, MSc, FACP, interviews urologist Neal D. Shore, MD, FACS, on the top updates in prostate cancer and bladder cancer at the 2025 European Society for Medical Oncology Congress.

Explore the complexities of treatment options for metastatic hormone-sensitive prostate cancer, emphasizing shared decision-making and patient considerations.

Research explores the effectiveness of Aerote in treating metastatic hormone-sensitive prostate cancer, focusing on patient subgroups and genetic factors.

Explore the potential of ultra-low PSA testing in managing metastatic hormone-sensitive prostate cancer, balancing accessibility and cost considerations.

Explore the latest advancements in clinical trials for metastatic hormone-sensitive prostate cancer, focusing on innovative treatments and testing methods.

Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency.

Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency.

Research reveals that lower PSA levels in metastatic hormone-sensitive prostate cancer significantly delay disease progression and improve patient outcomes.

Research highlights the significant benefits of achieving ultra-low PSA levels in metastatic hormone-sensitive prostate cancer, delaying disease progression effectively.

A panelist discusses how ARANOTE contributes to the evidence for treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), comparing it with other trials like ARCHES, TITAN, and LATITUDE while highlighting the nuanced differences in adverse effect profiles and tolerability among these agents.

A panelist discusses how the ARANOTE phase 3 trial investigated darolutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, providing an overview of the study design and topline results.

Neal D. Shore, MD, FACS, shares the background and key findings from the phase 3 CREST trial, exploring sasanlimab plus BCG for BCG-naive NMIBC.

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

Panelists examine disease heterogeneity in NMIBC and discuss a balanced treatment approach that prioritizes patient quality of life and surgery effectiveness.

Panelists examine disease heterogeneity in NMIBC and discuss a balanced treatment approach that prioritizes patient quality of life and surgery effectiveness.

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

Neal Shore, MD, FACS, highlights the exciting advancements in radioligand therapy for prostate cancer, noting that ongoing trials are exploring its use in various disease stages and settings, and emphasizes the importance of reviewing the VISION and FORE trial publications for further insights.

Neal Shore, MD, FACS, discusses the evolving use of follow-up PSMA PET scans and the recent FORE trial, which showed that Lutetium-177 improves radiographic progression-free survival and PSA levels in prechemotherapy patients with mCRPC, with more data on overall survival and quality of life expected.

Neal Shore, MD, FACS, emphasizes the significance of the VISION and TheraP trials in supporting the FDA approval of Lutetium-177 for patients with mCRPC who have undergone androgen receptor inhibitor and taxane treatments, highlighting the role of PSMA PET imaging in treatment sequencing and patient selection.

Neal Shore, MD, FACS, discusses how the patient profile in the VISION trial, which involved progression on multiple therapies, reflects typical cases for Lutetium-177 treatment, emphasizing the crucial role of PSMA PET imaging in determining treatment suitability.

Neal Shore, MD, FACS, discusses the progress of a 65-year-old patient with mCRPC through various treatments and evaluation for Lutetium-177 therapy based on his PSMA PET scan and MRI.

Neal Shore, MD, FACS, and Brian Shuch, MD, provide closing thoughts on the potential of PET/CT imaging to improve patient care in kidney cancer.

Urologists review clinical trials investigating new imaging options in kidney cancer, including the ZIRCON study looking at girentuximab.